As an alternative to the tandem, costransduction, and bicistronic products reviewed thus far, Pan et al. [44] evaluated sequential CD19 and CD22 CAR T cell infusions in a phase 1 trial involving 20 pediatric patients with R/R B-ALL [44]. Here, CD22 is linked to acute lymphoblastic leukemia.